[{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2024-07-02T16:35:06.921Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-30"},{"id":"a65eaf0b-f986-4662-a858-795fc0730939","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273139","created_at":"2021-01-18T20:45:24.651Z","updated_at":"2024-07-02T16:35:08.111Z","phase":"Phase 2","brief_title":"Ibrutinib + Venetoclax in Untreated WM","source_id_and_acronym":"NCT04273139","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 mutation","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 06/06/2022","primary_completion_date":" 06/06/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-04-23"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"15d7a52b-337d-4b37-8862-81c425e8dbd7","acronym":"WAL-KU","url":"https://clinicaltrials.gov/study/NCT02640287","created_at":"2021-01-18T12:50:33.419Z","updated_at":"2024-07-02T16:36:26.833Z","phase":"","brief_title":"Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT02640287 - WAL-KU","lead_sponsor":"Central Hospital, Nancy, France","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-08-06"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"}]